Drug Search Results
More Filters [+]

Peramivir

Alternative Names: peramivir, rapivab
Latest Update: 2024-07-01
Latest Update Note: News Article

Product Description

Peramivir (BioCryst Pharmaceuticals) is a novel investigational intravenous neuraminidase inhibitor that exhibits potent antiviral activity against influenza A and B viruses. Peramivir is created by a structure-based drug design and consists of a cyclopentane backbone with a positively charged guanidinyl group and lipophilic side chains. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22339187/)

Mechanisms of Action: NEU Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Inhalant

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Belgium | Canada | European Medicines Agency | Germany | Hungary | Ireland | Italy | Japan | Korea | Lithuania | Poland | Portugal | Sweden | Taiwan | United States

Approved Indications: Influenza, Human

Known Adverse Events: Diarrhea

Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Peramivir

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20131184

P3

Recruiting

Influenza, Human

None

CTR20131182

P3

Recruiting

Influenza, Human

None

Recent News Events